Recruiting

Role of Microvascular Insulin Resistance and Cardiorespiratory Fitness Diabetes

The goal of this two-site grant proposal is to determine the role of the decreased insulin-mediated muscle perfusion found in type 2 diabetes in contributing to the development of cardiac and skeletal muscle dysfunction and subsequent functional exercise impairment. In addition, it is also our goal to determine whether exercise training attenuates insulin resistance and restores insulin-mediated perfusion to the heart and to skeletal muscle, leading to improved cardiac function and exercise performance.

ClinicalTrials.gov IDNCT04791371
PhaseNA
Enrollment150
SponsorUniversity of Colorado, Denver
Age30 Years
SexALL
I'm interested View official listing

Conditions studied

Type 2 Diabetes, Overweight and Obesity

About this study

The goal of this two-site grant proposal is to determine the role of the decreased insulin-mediated muscle perfusion found in type 2 diabetes in contributing to the development of cardiac and skeletal muscle dysfunction and subsequent functional exercise impairment. In addition, it is also our goal to determine whether exercise training attenuates insulin resistance and restores insulin-mediated perfusion to the heart and to skeletal muscle, leading to improved cardiac function and exercise performance.

Interventions

Primary outcomes

Eligibility information

Inclusion Criteria: * Sedentary (defined as less than 1 hour per week of physical activity) * BMI: 25-40 * Men and women with and without type 2 diabetes Exclusion Criteria: * Documented cardiovascular disease * Uncontrolled hypertension: disease systolic blood pressure (SBP) \> 150, diastolic blood pressure (DBP)\> 110 * Obstructive pulmonary disease or asthma * Peripheral neuropathy * Physical impairment that would limit exercise ability * Subjects taking beta blockers, calcium channel blockers, insulin, or Thiazolidinediones (TZD) * Current or past smoking within the last 1 years * Current tobacco use * Anemia * Control HbA1c \> 5.7, T2DM HbA1c \> 9 * Pregnant, nursing or hormonal therapy (other than contraceptives) * Peri or post-menopausal women * Type 1 diabetes * Hepatic or renal disease.

Study locations

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.